Articles for Specialty Pharmaceuticals, Filtered by: Research
March 17, 2015 | James G. Stevenson, PharmD, FASHP; and Keith Bruhnsen, MSW
Description of strategies that employers can consider to better manage their PBM relationship to optimize their pharmacy benefit costs.
June 19, 2014 | Martin Zalesak, MD, PhD; Joyce S. Greenbaum, BA; Joshua T. Cohen, PhD; Fotios Kokkotos, PhD; Adam Lustig, MS; Peter J. Neumann, ScD; Daryl Pritchard, PhD; Jeffrey Stewart, BA; and Robert W. Dubois, MD, PhD
This study examines whether patients treated with specialty pharmaceuticals have improved outcomes compared with patients treated with conventional therapies, and evaluates costs associated with these treatments.
August 2, 2012 | William N. Kelly, PharmD, FISPE; Jeoffrey Stross, MD; James Jorgenson, MS, RPH, FASHP; and Douglas E. Miller, PharmD
Strategies for controlling use of specialty pharmaceuticals should focus on situations where these agents are used inappropriately and on improvement of the complex billing process.
January 11, 2011 | James A. Jorgenson, RPh, MS
Over the last 20 years, specialty pharmacy has grown and changed significantly to better manage high-cost drugs with challenging reimbursement issues.
April 26, 2010 | Jan E. Berger, MD, MJ
Can value-based benefit design be used in specialty pharmacy to address costs and align incentives between patients and payers?